PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury

Elshazly, Shimaa M.; Soliman, Eman

doi:10.1016/j.taap.2018.10.022

Cited by 47 publications

(23 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renal I/R mostly affects vital organs such as the heart, liver, and lung. Previous studies have indicated that renal I/R led to excessive oxidative stress and increased inflammatory responses (Elshazly & Soliman, 2019;Kelly, 2003;Mitaka et al, 2014…”

Section: Discussionmentioning

confidence: 99%

“…Although most of these patients receive renal plasma treatment, the treatment is often insufficient to protect patients from the high risk of death. Renal I/R damage causes multiple organ dysfunctions and a high risk of death, usually occurs as a result of this condition (Dépret et al., 2017; Elshazly & Soliman, 2019; Shih et al., 2018; Yap & Lee, 2012). In the renal I/R damage, the amount of reactive oxygen species (ROS) and cytokine levels increase, leading to excessive inflammatory responses (Kalogeris et al., 2012; Mitaka et al., 2014; Zhao et al., 2018).…”

Section: Introductionmentioning

confidence: 99%

“…The imbalance between ROS production and elimination leads to an increase in oxidative stress. An increasing number of studies have revealed that renal I/R is related to decreased levels of enzymatic and nonenzymatic antioxidants, and accumulation of intracellular ROS (Elshazly & Soliman, 2019; Karim et al., 2015; Wang et al., 2010). Renal I/R injury causes damage to remote organs such as the lung, heart, and liver (Dépret et al., 2017; Yap & Lee, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ameliorative effect of umbelliferone in remote organ injury induced by renal ischemia‐reperfusion in rats

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ameliorative effect of umbelliferone in remote organ injury induced by renal ischemia‐reperfusion in rats

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence suggested that PPARc agonists could also provide a protection in wider spectrum of kidney diseases, such as the acute nephrotic syndrome, nondiabetic glomerulosclerosis, and the polycystic kidney [96,97]. Pioglitazone was reported to improve the renal functions in animal models of renal ischemia reperfusion-induced AKI via regulating Tnf and Nrf2 expression [98]. Furthermore, recent studies have highlighted beneficial roles of PPARc agonists for patients with chronic renal failure, hemodialysis, as well as peritoneal dialysis (PD) could also benefit from [99,100].…”

Section: Clinical Application Of Pparγ Agonist In Kidney Diseasesmentioning

confidence: 99%

PPARγ and Its Agonists in Chronic Kidney Disease

Shi

Wang

et al. 2020

International Journal of Nephrology

View full text Add to dashboard Cite

Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible end-stage renal diseases (ESRD) or renal failure. e major risk factors for CKD include obesity, diabetes, and cardiovascular diseases. Understanding the key process involved in the disease development may lead to novel interventive strategies, which is currently lagging behind. Peroxisome proliferator-activated receptor c (PPARc) is one of the ligand-activated transcription factor superfamily members and is globally expressed in human tissues. Its agonists such as thiazolidinediones (TZDs) have been applied as effective antidiabetic drugs as they control insulin sensitivity in multiple metabolic tissues. Besides, TZDs exert protective effects in multiple other CKD risk disease contexts. As PPARc is abundantly expressed in major kidney cells, its physiological roles in those cells have been studied in both cell and animal models. e function of PPARc in the kidney ranges from energy metabolism, cell proliferation to inflammatory suppression, although major renal side effects of existing agonists (including TZDs) have been reported, which limited their application in treating CKD. In the current review, we systemically assess the function of PPARc in CKDs and the benefits and current limitations of its agonists in the clinical applications.

show abstract

“…Even though pioglitazone could inhibit liver injury in the present studies, it could not inhibit factors associated with inflammation such as IL-6 or TNF-α and did not inhibit the very expensive liver metastasis observed. In the present study, tumor growth was effected by splenic injection of cancer cells which was shown to induce high levels of liver metastasis due to the association of cancer cells with splenocytes 20 – 23 . Our hypothesis is that pioglitazone may have different effects depending on route of administration and schedule.…”

Section: Discussionmentioning

confidence: 77%

Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer

Tashiro

Nishino

Higuchi

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer may increase the risk of further metastasis. Peroxisome proliferator-activated receptor-γ (PPARγ) activation has been observed to exert a protective effect against IRI and IRI-induced metastasis of hepatocellular carcinoma. The present study aimed to investigate the effect of the PPARγ agonist pioglitazone on tumor metastasis and liver injury following IRI in a mouse model of colon cancer. Pioglitazone (30 mg/kg weight) was administered orally 1.5 h before and 2 h after the initiation of ischemia and was orally administrated daily to mice from day 0–21. SL4-cancer cells expressing red fluorescent protein (SL4-RFP) (1 × 106) were injected into the spleen. Fifteen minutes after injection, the hepatoduodenal ligament was clamped with a vessel clip, and released 5 min later. Liver, blood and tumor samples were taken from mice in order to determine if inflammation was induced by IRI. The effect of pioglitazone on liver metastasis was assessed. Furthermore, the effect of pioglitazone to control the inflammatory response during IRI progression was examined. Liver metastasis along with MMP-9 activation and the production of inflammatory cytokines were resistant to pioglitazone. Our results indicate that liver metastasis and associated inflammation in mice were resistant to pioglitazone.

show abstract

PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury

Cited by 47 publications

References 51 publications

Ameliorative effect of umbelliferone in remote organ injury induced by renal ischemia‐reperfusion in rats

Ameliorative effect of umbelliferone in remote organ injury induced by renal ischemia‐reperfusion in rats

PPARγ and Its Agonists in Chronic Kidney Disease

Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer

Contact Info

Product

Resources

About